Therapy News and Research

RSS

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.

13 Jul 2010

Doctors should use diffusion MRI scan to diagnose stroke, says new guideline

Doctors should use a diffusion MRI scan to diagnose stroke instead of a CT scan, according to a new guideline from the American Academy of Neurology. The guideline is published in the July 13, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

13 Jul 2010

Silicon oil appears to protect vision in patients undergoing radiation therapy for ocular melanoma: Study

Eye cancer patients face an unenviable dilemma. They must enter treatment knowing that their surgeon's strategy to kill the deadly tumor with radiation may also sacrifice their eyesight.

13 Jul 2010

New study shows SAVI radiation therapy controls rate of breast cancer

A new study of breast cancer patients at the Moores UCSD Cancer Center and the Arizona Oncology Services shows that after almost two years, the radiation given with the Strut-Adjusted Volume Implant controls the rate of cancer and may reduce the complications seen with alternate types of brachytherapy.

13 Jul 2010

Stem cell transplantation from healthy donor helps cure aggressive form of CLL

The transplantation of stem cells from a healthy donor (allogeneic) offers the chance of cure for patients with an aggressive form of chronic lymphocytic leukemia (CLL), irrespective of genetic prognostic factors and the prior course of the disease. The German CLL Study Group proved this in a multicentric clinical phase II study led by Professor Dr. Peter Dreger, senior consultant and head of the division of stem cell transplantation at the Department of Internal Medicine V at Heidelberg University Hospital.

13 Jul 2010

GWAS suggests genetic variant with increased oncogene expression for cancer study

The study, published July 13th in Genome Research, showcases a new protocol for studying the activity of cancer-risk variants suggested by GWAS studies. The results also underscore the dramatic consequences of small genetic changes even in the vast stretches of DNA, known as "gene deserts," that do not code for proteins.

13 Jul 2010

Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards announced

URAC announced today that a distinguished panel of judges has selected 30 finalists for its Best Practices in Health Care Consumer Empowerment and Protection Awards. The competition drew entries from across the nation. The finalists will be honored during URAC's 11th Annual Quality Summit, October 5-7, 2010 in Chicago, IL. The awards honor programs in two areas: Consumer Decision-Making and Consumer Health Improvement.

13 Jul 2010

Preclinical results of TH-302 presented at AACR Translational Cancer Medicine Meeting

Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.

13 Jul 2010

OvaGene Oncology completes license agreements with key Norwegian cancer researchers

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today that it has completed license agreements with key Norwegian cancer researchers. The agreements allow OvaGene to validate two new promising genomic technologies with the intention of developing these into clinical laboratory tests.

13 Jul 2010

Research findings could offer new approach to diabetes therapy, nutrition experts say

Nutrition experts at Oregon State University have essentially "cured" laboratory mice of mild, diet-induced diabetes by stimulating the production of a particular enzyme. The findings could offer a new approach to diabetes therapy, experts say, especially if a drug could be identified that would do the same thing, which in this case was accomplished with genetic manipulation.

13 Jul 2010

Efficacy data of Caldolor Injection in treating fever associated with falciparum malaria published

Cumberland Pharmaceuticals Inc. today announced that data supporting the efficacy of Caldolor in treating fever associated with falciparum malaria was published in the July edition of the peer-reviewed American Journal of Tropical Medicine and Hygiene. The study, which is the first to document an antipyretic effect of an injectable non-steroidal anti-inflammatory drug on fever caused by malaria, demonstrated that patients who received intravenous ibuprofen experienced a greater reduction in their temperatures than those who received placebo.

13 Jul 2010

BSD receives FDA review questions for Phase II MTX-180 Microwave Ablation System 510(k) submission

BSD Medical Corporation today announced that it has received review questions from the U.S. Food and Drug Administration (FDA) regarding the 510(k) submission the Company filed for premarket clearance of the Company's Phase II MicroThermX® Microwave Ablation System (MTX-180) for ablation of soft tissue.

12 Jul 2010

OICR, CCO announce $6 million in funding for Health Services Research Program projects

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), and Dr. Terrence Sullivan, President and CEO of Cancer Care Ontario (CCO), announce $6 million in funding for projects in the Health Services Research Program (HSRP). The HSRP, conducted jointly between the OICR and CCO, will improve the delivery of cancer care throughout the province.

12 Jul 2010

Accumetrics, Daiichi Sankyo, Eli Lilly collaborate to raise awareness about antiplatelet therapy

Accumetrics, Inc., Daiichi Sankyo, Inc, and Eli Lilly and Company announced today that the companies have entered into a strategic collaboration in the United States to raise awareness about antiplatelet therapy and the role of platelet function testing.

12 Jul 2010

Reata funds second pivotal trial of bardoxolone with $78 million equity financing

Reata Pharmaceuticals, Inc. has completed a $78 million equity financing led by existing investors CPMG, Inc. and Novo A/S. This financing brings the total raised by the Company to $180 million since inception.

12 Jul 2010

Experimental anti-obesity and diabetes drug avoids risk of psychiatric side effects: Study

A second-generation experimental anti-obesity and diabetes drug has shown promise in reducing body weight in rodents just as effectively as the predecessor rimonabant while avoiding the risk of psychiatric side effects that led to the withdrawal of rimonabant from the market and stopped further development of other brain-penetrating drugs of its type.

12 Jul 2010

Manuscript based on study of Clarient InsightDx Mammostrat to be published in Breast Cancer Research

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that a manuscript based on a study of Clarient InsightDx Mammostrat, a test used to classify the risk of recurrence of breast cancer following surgery and chemotherapy, will be published in an upcoming edition of Breast Cancer Research, a prominent peer-reviewed medical journal.

12 Jul 2010

Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1

Medivir announced today 24-week end-of-treatment interim results from the 5-arm phase 2b response guided PILLAR study in 386 treatment-naïve patients with hepatitis C virus (HCV) genotype-1 (TMC435-C205).

12 Jul 2010

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Julianna Lisziewicz, PhD, President of Genetic Immunity, a biopharmaceutical company developing nanomedicine-based immunotherapies, is an invited speaker at this week's 7th International Conference on Nanosciences & Nanotechnologies in Ouranoupolis Halkidiki, Greece. The conference gathers front-line researchers, scientists and industry experts specialized in nanotechnology applications. Leading experts such as Dr. Lisziewicz are invited to present lectures covering the latest research in this rapidly progressing field.

12 Jul 2010

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.

12 Jul 2010

Therapy News and Research

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

Doctors should use diffusion MRI scan to diagnose stroke, says new guideline

Silicon oil appears to protect vision in patients undergoing radiation therapy for ocular melanoma: Study

New study shows SAVI radiation therapy controls rate of breast cancer

Stem cell transplantation from healthy donor helps cure aggressive form of CLL

GWAS suggests genetic variant with increased oncogene expression for cancer study

Finalists for Best Practices in Health Care Consumer Empowerment and Protection Awards announced

Preclinical results of TH-302 presented at AACR Translational Cancer Medicine Meeting

OvaGene Oncology completes license agreements with key Norwegian cancer researchers

Research findings could offer new approach to diabetes therapy, nutrition experts say

Efficacy data of Caldolor Injection in treating fever associated with falciparum malaria published

BSD receives FDA review questions for Phase II MTX-180 Microwave Ablation System 510(k) submission

OICR, CCO announce $6 million in funding for Health Services Research Program projects

Accumetrics, Daiichi Sankyo, Eli Lilly collaborate to raise awareness about antiplatelet therapy

Reata funds second pivotal trial of bardoxolone with $78 million equity financing

Experimental anti-obesity and diabetes drug avoids risk of psychiatric side effects: Study

Manuscript based on study of Clarient InsightDx Mammostrat to be published in Breast Cancer Research

Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News